More reads
- CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study. (STAT Plus)
- Americans are paying twice for remdesivir. (Slate)
- Gilead adds to string of cancer drug deals with Tizona stake. (BioPharma Dive)
- STAT+ Conversations: AI’s march into the clinic. (STAT Plus)
No hay comentarios:
Publicar un comentario